Advancing excellence in laboratory medicine for better healthcare worldwide

Education in the Use of Biomarkers in Diabetes (C-EUBD)

Membership

NamePositionCountryTermTime in Office
G. JohnChairUK2nd2019 01 - 2021 12
E. EnglishMemberUK2nd2019 01 - 2021 12
A. SatoMemberJP1st2019 03 - 2021 12
D. SacksMemberUS2nd2019 01 - 2021 12
C. WeykampMemberNL2nd2019 01 - 2021 12
E.Lenters-WestraConsultantNL

Terms of reference

  1. To maintain and further develop the network of reference laboratories for the measurement of HbA1c (through collaboration with C-TLM)
  2. To work in partnership with WHO and IDF to continue to promote the reporting of HbA1c in line with the consensus statement
  3. To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA1c in the diagnosis of diabetes
  4. To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA1c methods
  5. Develop quality targets for the measurement of HbA1c and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
  6. To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA1c
  7. To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
  8. To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
  9. To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.

List of Corresponding Members, nominated by National Societies

NameIFCC Member Society
D. AslanTurkish Biochemical Society (TBS)
W. Cheneke GebisaEthiopian Medical Laboratory Association (EMLA)
E. SchleicherDeutche Gesellschaft fur Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL)
A. MoscaItalian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC)
A. CojLithuanian Society of Laboratory Medicine
R. Kumar DubeyNepalese Association for Clinical Chemistry (NACC)
B. Kumar YadavNepalese Association for Laboratory Science (NAMLS)
B. OkesinaAssociation of Clinical Chemists Nigeria (ACCN)
R. NandaAssociation of Medical Biochemists of India (AMBI)
P. GillerySociété Francaise de Biologie Clinique (SFBC)

List of Corresponding Members, nominated by Corporate Members

NameCompany
S. BaraldiA. Menarini Diagnostics
R. MolinaroSiemens Healthcare

Committee Chair's contact

Prof. Garry JOHN
Consultant Clinical Biochemist
and Head of Clinical Biochemistry
Norfolk and Norwich University Hospital
UK
Tel: +44 (0) 1603 286 933

 
Website developed by Insoft